TARGET
  • Home
  • About TARGET
    • Our Team
    • Specific Aims
    • Background and Significance
    • Study Design
    • Ancillary Studies
    • TARGET in the News
  • Interested Patients
    • Contact Us
    • Find a Site
  • For Participants
    • Injecting
    • Injection Site Reactions
    • Pre-scan diet
    • Remembering your Meds
  • Journal Club
  • Newsletters
  • For Study Sites
    • Advertisements
    • Coordinator Resources
    • Imaging Information
    • Laboratory Information
    • Monthly Call Slides
    • October Meeting
    • Pre-Screen Log
    • Regulatory Documents >
      • Current Documents
      • Approved ICFs
      • Amendment Details
      • Central IRB Setup
    • Training >
      • Investigator Training
      • Coordinator Training
      • Metrologist Training
      • Imaging Training >
        • Imaging Refresher Training
      • Electronic Data Capture (EDC)

Specific Aims

Picture
Aim 1: To compare the effects on vascular inflammation of two commonly prescribed therapies in patients with RA who do not have improved RA symptoms when taking methotrexate alone. We hope to show that TNF inhibitors, such as Enbrel and Humira, will reduce cardiac inflammation to a greater extent than triple therapy will after 6 months. Both treatments have recently been shown to be equally as effective in reducing pain, improving patient function, and curbing the severity and frequency of RA symptoms. For now, it remains unclear whether the quicker relief of joint inflammation by TNF antagonists would translate into a greater reduction of vascular inflammation.

Picture

Aim 2:

To compare vascular inflammation in subjects who do and do not achieve remission after six months on their new therapies.  We hope to show that subjects in disease remission will have less vascular inflammation than those who do not reach remission.
Picture

Aim 3:

To compare the effects of the alternative treatments on joint inflammation. We hope to show that joint inflammation will be more reduced in subjects using Enbrel or Humira and taking methotrexate as compared to those on triple therapy. While patients on these therapies feel the same, we wonder whether imaging will reveal that their joints have different levels of inflammation.
Picture

Aim 4:

To examine the relationship between certain compounds in a patient's blood and vascular inflammation. These compounds, known as biomarkers, can now be used to identify a patient's risk of Cardiovascular disease and severity of RA symptoms. These biomarkers include IL-6, CRP, serum amyloid protein, fibrinogen, ICAM-1, and Vecta DA, a multi-marker indicator of systemic inflammation in RA. Data from this trial will be used to inspire and carry out future studies. 
Learn More
Home
About

Contact
TARGET (Treatments Against RA and Effects on FDG-PET/CT)
Funded by NIAMS
Picture
Picture
  • Home
  • About TARGET
    • Our Team
    • Specific Aims
    • Background and Significance
    • Study Design
    • Ancillary Studies
    • TARGET in the News
  • Interested Patients
    • Contact Us
    • Find a Site
  • For Participants
    • Injecting
    • Injection Site Reactions
    • Pre-scan diet
    • Remembering your Meds
  • Journal Club
  • Newsletters
  • For Study Sites
    • Advertisements
    • Coordinator Resources
    • Imaging Information
    • Laboratory Information
    • Monthly Call Slides
    • October Meeting
    • Pre-Screen Log
    • Regulatory Documents >
      • Current Documents
      • Approved ICFs
      • Amendment Details
      • Central IRB Setup
    • Training >
      • Investigator Training
      • Coordinator Training
      • Metrologist Training
      • Imaging Training >
        • Imaging Refresher Training
      • Electronic Data Capture (EDC)